Advancing traditional prostate-specific antigen kinetics in the detection of prostate cancer: A machine learning model Journal Article


Authors: Perera, M.; Smith, L.; Thompson, I.; Breemer, G.; Papa, N.; Patel, M. I.; Swindle, P.; Smith, E.
Article Title: Advancing traditional prostate-specific antigen kinetics in the detection of prostate cancer: A machine learning model
Abstract: Background: Prostate-specific antigen (PSA) kinetics, defined as the change in PSA over time, may be of use as a predictor of prostate cancer. PSA kinetics can be assessed as the PSA velocity, which is traditionally evaluated dichotomously and classified as abnormal if greater than either 0.35 or 0.75 ng/ml/yr. Machine learning models may provide additional benefit in assessing risk using PSA kinetics instead of PSA velocity. Objective: To improve the utility of PSA kinetics by constructing a generalizable, universal machine learning model. Design, setting, and participants: Data were obtained from the PLCO and PCPT trials and from a contemporary Australian cohort. PSA data were interpolated using a modified Gaussian process. A machine learning model based on a two-headed approach was designed, in which the multivariable input was fed into a one-dimensional ResNet18 model. Outcome measures and statistical analysis: The model performance was assessed compared to PSA levels and PSA velocity in terms of area under the receiver operator characteristic curve (AUC). Results and limitations: A total of 10 719 patients were included in the analysis. In tests on a validation set of the complete database to diagnose grade group ≥2, the AUC was 0.886 (95% confidence interval [CI] 0.870–0.902) for the machine learning model, compared to 0.807 (95% CI 0.796–0.819) for PSA and 0.627 (95% CI 0.607–0.648) for PSA velocity. Conclusions: Machine learning models can be used to augment the diagnostic utility of PSA kinetics in the diagnosis of prostate cancer. We demonstrated significant improvements in accuracy compared to the traditional approaches of PSA velocity and PSA thresholds. Patient summary: Prostate cancer diagnosis is limited by the diagnostic accuracy of the prostate-specific antigen (PSA) blood test. Advances in techniques such as machine learning algorithms can greatly improve the diagnostic accuracy of prostate cancer screening without additional costs or tests. © 2021 European Association of Urology
Keywords: biomarkers; prostate specific antigen; risk factors; risk factor; risk assessment; prostate cancer; prostate-specific antigen; prostatic neoplasms; kinetics; prostate tumor; australia; early detection of cancer; procedures; machine learning; humans; human; male; early cancer diagnosis
Journal Title: European Urology Focus
Volume: 8
Issue: 5
ISSN: 2405-4569
Publisher: Elsevier B.V.  
Date Published: 2022-09-01
Start Page: 1204
End Page: 1210
Language: English
DOI: 10.1016/j.euf.2021.11.009
PUBMED: 34920976
PROVIDER: scopus
PMCID: PMC9253978
DOI/URL:
Notes: Article -- Export Date: 3 January 2023 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Marlon Lakmal Perera
    24 Perera